A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Aplastic Anemia & MDS International Foundation Return to top.
A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Clinical Trial: NCT03406507

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The purpose of this study is to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of ALXN1210 in pediatric patients with paroxysmal nocturnal hemoglobinuria (PNH).

Status: 
Recruiting
Study Date: 
Thu, 02/22/2018 ( ) to Mon, 08/01/2022 ( )
Intervention: 
Experimental: ALXN1210 Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
Share with addtoany.com.